论文部分内容阅读
乳腺小黏蛋白(small hreast epithelialmucin,SBEM)是一种分泌性蛋白,仅在乳腺及唾液中表达,可作为乳腺癌患者微转移的分子标志物及其治疗的特异性靶标。SBEM在乳腺癌组织中蛋白水平检出率最高达51%,在外周血中mRNA水平检出率最高达53.3%,且与乳腺癌患者的TNM分期直接相关。SBEM-mRNA与角蛋白19 mRNA(CK19-mRNA)、泌乳素诱导蛋白(PIP-mRNA)及癌胚抗原(CEA)的联合检测,能够提高乳腺癌患者微转移的检出率及敏感度和准确度,SBEM-mRNA表达水平变化的检测可应用于新辅助化疗疗效预测,并对骨髓微转移的诊断具有特异性和准确性,且与肿瘤的分期密切相关,在临床中有较好的应用前景。本文就SBEM的表达、与临床病理参数的关系、联合检测的意义及其应用价值等做一综述。
Small hreast epithelial mucus (SBEM) is a secreted protein that is expressed only in breast and saliva and can be used as a molecular marker for micrometastasis in breast cancer patients and as a specific target for its treatment. The detection rate of SBEM in breast cancer tissue is up to 51%, the highest detection rate of mRNA in peripheral blood is 53.3%, which is directly related to the TNM stage in breast cancer patients. The combined detection of SBEM-mRNA with CK19-mRNA, PIP-mRNA and CEA can improve the detection rate and sensitivity of breast cancer patients with micrometastases The detection of the changes of SBEM-mRNA expression level can be applied to the prediction of the efficacy of neoadjuvant chemotherapy, and has the specificity and accuracy in the diagnosis of bone marrow micrometastasis. It is closely related to the stage of the tumor and has a good application prospect in the clinic . This article reviews the expression of SBEM, the relationship with clinicopathological parameters, the significance of joint detection and its application value.